Ranjan Pai's Med-Tech Vision: Shravan Subramanyam Joins Claypond Capital

Claypond Capital welcomes Shravan Subramanyam as the head of its med-tech platform. With a rich background in healthcare and a focus on digital solutions, Subramanyam aims to expand South Asia's med-tech presence. The Indian medical devices sector is poised for promising growth in the coming decade.

Claypond Capital, the investment firm under Manipal Group chairman Ranjan Pai, has appointed Shravan Subramanyam to spearhead its medical technology platform. Subramanyam, formerly Managing Director at Wipro-GE Healthcare, brings two decades of experience in life sciences and medical devices.

An alumnus of Madras Medical College and Cornell University, Subramanyam envisions a decade of medical innovation, particularly in digital technology, aiming to enhance the reach of med-tech firms in South Asia and globally. His previous roles include leadership positions at Roche and Novartis.

Ranjan Pai emphasized the transformative role of med-tech in post-Covid healthcare, highlighting a strategy that combines long-term capital with industry-academia partnerships. India's medical devices market, valued at Rs 1.2 lakh crore in 2023-24, is expected to grow at 11% annually through 2032.

(With inputs from agencies.)